Key result
Low-molecular-weight heparins demonstrate high efficacy and low risk for the prophylaxis and treatment of arterial thrombosis.
Why the study?
Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi?
Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi?
LMWHs offer a favorable efficacy and safety profile, including lower bleeding and HIT risks, for the management of arterial thrombosis.
Supports LMWH use in arterial thrombosis; hypothesis-generating pending randomized confirmation.
The pharmacologic specificity of low-molecular-weight heparins (LMWHs) has enabled multiple attractive developments in the prophylaxis and treatment of arterial thrombosis. Their high antithrombotic potency associated with a potentially lower induced bleeding risk, the lack of platelet interaction, the prevention of myointimal hyperplasia, and the lower incidence of heparin-induced thrombocytopenia, are major advantages. New studies in cardiology and vascular surgery demonstrate a high efficacy for LMWHs associated with a low risk.
No takes yet. Share an insight, caveat, or question.
Samama et al. (2009) conducted a review in Arterial thrombosis. Low-molecular-weight heparins (LMWHs) was evaluated. Low-molecular-weight heparins demonstrate high efficacy and low risk for the prophylaxis and treatment of arterial thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: